Publications - IR Sant Pau

Search

01/01/2026 A New Horizon for an Old Disease: Modern Strategies for Approaching Chronic Cough

Domingo, C, Crespo-Lessmann, A, McGarvey, L. A New Horizon for an Old Disease: Modern Strategies for Approaching Chronic Cough. ARCHIVOS DE BRONCONEUMOLOGIA. 2026; 62(1)DOI:10.1016/j.arbres.2025.07.020. PMID:40887323. IF:9.200(Q1/1D).

01/01/2026 Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD

Casanova, C, Gonzalez-Dávila, E, De Torres, JP, Cabrera, C, Cosio, BG, O'Donnel, DE, Martínez-Gonzalez, C, Solanes, I, Fuster, A, Gotera, C, Marin, A, Amado, C, Iscar, M, Marin, JM, Neder, JA, Feu, N, Soriano, JB, López-Campos, JL, Divo, M, Peces-Barba, G, Celli, BR. Lung Diffusing Capacity Improves the Prognostic Validity of the GOLD Spirometric Staging in COPD. ARCHIVOS DE BRONCONEUMOLOGIA. 2026; 62(1)DOI:10.1016/j.arbres.2025.05.004. PMID:40447521. IF:9.200(Q1/1D).

01/01/2026 Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease

Viglino, J, Perea, L, Garcia-Nuñez, M, Rodrigo-Troyano, A, Torrego, A, Domínguez-Alvarez, M, Villar, J, Carrizosa, X, Quero, S, Gabaldon, T, Willis, JR, Saus, E, Gea, J, Santos, S, Camps, P, Agusti, A, Monso, E, Sibila, O, Faner, R. Characterisation of the gut-lung axis microbiome in clinically stable patients with chronic obstructive pulmonary disease. EBioMedicine. 2026; 123DOI:10.1016/j.ebiom.2025.106099. PMID:41483682. IF:10.800(Q1/1D).

01/12/2025 Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort

Betancor, D, Rial, MJ, Olaguibel, JM, Del Pozo, V, Puebla, MJA, Arismendi, E, Barroso, B, Bobolea, I, Cárdaba, B, Cañas, JA, Domínguez-Ortega, J, Crespo-Leshman, A, Cruz, MJ, de la Fuente, AG, González-Barcalai, FJ, Luna-Portac, JA, Martínez-Rivera, C, Mullol, J, Muñoz, X, Plaza, V, Quirce, S, Soto-Retes, L, Valverde-Monge, M, Sastre, J. Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort. ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(12)DOI:10.1016/j.arbres.2025.06.016. PMID:40707281. IF:9.200(Q1/1D).

01/12/2025 Early Failure, Late Failure, and Sustained Response to Biologics in Severe Asthma: A Long-term, Real-world, Multicentre study

Rivas, DD, Martinez-Moragon, E, Plaza, V, Serrano, CC, Benchimol, C, Flores, HI, Sánchez-Cuéllar, S, Martinez-Pitarch, MD, Aracil, CF, Alonso, AT, Rebollo, JCS, Gambasica, ZV, Campos, RMD, Mulato, PT, Gimeno, IE, Laorden, D, Arismendi, E, Malanda, NM, Damia, AD, Galvan, MF, Dávila, I, Bobo, JOD, Cosio, BG, de Llano, LAP. Early Failure, Late Failure, and Sustained Response to Biologics in Severe Asthma: A Long-term, Real-world, Multicentre study. ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(12)DOI:10.1016/j.arbres.2025.04.003. PMID:40348717. IF:9.200(Q1/1D).

01/12/2025 Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine

Pascual, MB, Zapata-Huizi, JJ, Ramos, D, Francesqui, J, Alsina-Restoy, X, Hernández-González, F, Sellares, J. Biomarkers in Sarcoidosis: From Traditional Markers to Precision Medicine. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. 2025; 46(06)DOI:10.1055/a-2741-2030. PMID:41213628. IF:2.700(Q2/5D).

01/09/2025 Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study)

Moreno, BR, Benitez, ID, Erro, M, Burgos, J, Sayés, A, Garcia-Urrestarazu, EJ, Pou, C, Castan, RA, Navarro, A, Fuentes, AMD, Lakhani, JS, Juez-Garcia, I, Manzano, C, Santisteve, S, Morales, A, Monge, A, Moncusi-Moix, A, Sánchez-Cucó, A, Alcaide, AB, de-Torres, JP, Barbé, F, Suarez-Cuartin, G, de la Rosa, D, González, J. Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study). ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(9)DOI:10.1016/j.arbres.2025.04.008. PMID:40350352. IF:9.200(Q1/1D).

01/09/2025 Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders

Franquet, T, Brenes, JM, Radike, M, Giménez, A, Domingo, P. Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders. SEMINARS IN ULTRASOUND CT AND MRI. 2025; 46(4)DOI:10.1053/j.sult.2025.06.001. PMID:40543829. IF:1.900(Q3/6D).

01/01/2026 The hidden threat: HBV reactivation in the era of antiretroviral therapy optimization

Domingo, P, Stapleton, JT. The hidden threat: HBV reactivation in the era of antiretroviral therapy optimization. AIDS. 2026; 40(1)DOI:10.1097/QAD.0000000000004369. PMID:41489321. IF:3.100(Q2/4D).

16/12/2025 Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration

Timiryasova, A, Greenberg, L, Domingo, P, Tarr, PE, Egle, A, Martin, C, Mussini, C, Wit, F, Cingolani, A, Lehmann, C, Castagna, A, Petoumenos, K, Sabin, CA, Bonnet, F, Lundgren, J, Bottanelli, M, Hosein, S, Carlander, C, Amstutz, A, Grabmeier-Pfistershammer, K, Garges, H, Marongiu, A, Young, LA, Peters, L, Ryom, L. Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration. Cancers. 2025; 17(24)DOI:10.3390/cancers17244000. PMID:41463249. IF:4.400(Q2/3D).

01/10/2025 A plague like no other: beyond the buboes in Thucydides' account of the Plague of Athens

Domingo, P, Prieto, P, Pons, L. A plague like no other: beyond the buboes in Thucydides' account of the Plague of Athens. CLINICAL MICROBIOLOGY AND INFECTION. 2025; 31(10)DOI:10.1016/j.cmi.2025.05.001. PMID:. IF:8.500(Q1/1D).

01/10/2025 Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO study)

Monforte, A, Imaz, A, Ferrer, J, Piatti, C, Molero, M, Rodríguez, A, Stable, CE, Navarro, M, Prieto, P, Domingo, P, Crespo, M, Güerri-Fernández, R, Moltó, J, Navarro, J. Efficacy and tolerability of BIC/TAF/FTC in people with HIV and solid and hematological neoplasms: a multicenter observational study (BIKONCO study). HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

01/10/2025 High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study

Peters, L, Bannister, W, Sridhar, G, Gardizi, M, van Frankenhuijsen, M, De Scheerder, MA, Johansen, IS, Viard, JP, Duvivier, C, Bogner, J, Degen, O, Castagna, A, Staub, T, Martinez, E, Domingo, P, Moreno, S, Reikvam, DH, Parczewski, M, Knysz, B, Shivkar, Y, Brown, K, van Wyk, J, Vannappagari, V. High effectiveness and rare virologic failure in treatment-experienced individuals on long-acting cabotegravir plus rilpivirine therapy across Europe: Insights from the EuroSIDA study. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

01/10/2025 Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, openlabel, non-inferiority trial

Masia, M, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Garcia-Fraile, L, Blanco, JL, Ryan, P, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Gil, P, de Miguel, M, Alejos, B, Martinez, E. Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, openlabel, non-inferiority trial. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

01/10/2025 Hepatocellular carcinoma screening in HIV/HBV coinfected individuals: insights from Spain, Germany, and Poland

Berenguer, J, Ryan, P, Lutz, T, Martin-Carbonero, L, Pérez-Latorre, L, Vivancos, MJ, Navarro, J, Navarro-Soler, R, Ferrero, OL, Palacios, R, Wyen, C, Domingo, P, Monin, M, Camino, X, Montero-Alonso, M, Killer, A, Malin, J, De los Santos, I, Esser, S, Morano, LE, López, I, Valencia, J, Vogelmann, R, Mauss, S, Rivero, A, Elamouri, F, Hidalgo-Tenorio, C, Cielniak, I, Van Bremen, K, Pérez-Somarriba, J, Sanz, J, Rozplochowski, B, Beer, D, Baumgarten, A, Haberl, A, Galindo, MJ, Fariñas, C, Raczynska, A, Voit, F, Qurishi, N, Noe, S, Reus, S, Khaykin, P, Schneeweiss, S, Wandeler, G, Boyd, A, De Miguel, M, Bellón, JM, Parczewski, M, Rockstroh, J. Hepatocellular carcinoma screening in HIV/HBV coinfected individuals: insights from Spain, Germany, and Poland. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

01/10/2025 Prevalence and factors associated with liver cirrhosis in people with HIV and chronic hepatitis B: a cross-sectional study in Spain, Germany, and Poland

Ryan, P, Berenguer, J, Lutz, T, Martín-Carbonero, L, Pérez-Latorre, L, Vivancos, MJ, Navarro, J, Navarro-Soler, R, Ferrero, OL, Palacios, R, Wyen, C, Domingo, P, Monin, M, Camino, X, Montero-Alonso, M, Killer, A, Malin, JJ, De los Santos, I, Esser, S, Morano, LE, López, I, Cuevas, G, Vogelmann, R, Mauss, S, Rivero, A, Elamouri, F, Hidalgo-Tenorio, C, Cielniak, I, Van Bremen, K, Pérez-Somarriba, J, Sanz, J, Rozplochowski, B, Beer, D, Baumgarten, A, Haberl, A, Galindo, MJ, Armiñanzas, C, Raczynska, A, Voit, F, Qurishi, N, Christensen, S, Szymczak, A, Hlebowicz, M, Schwarze-zander, C, Jessen, A, Boyd, A, De Miguel, M, Bellon, JM, Parczewski, M, Rockstroh, J. Prevalence and factors associated with liver cirrhosis in people with HIV and chronic hepatitis B: a cross-sectional study in Spain, Germany, and Poland. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).

15/09/2025 Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV

Quesada-López, T, Mestres-Arenas, A, Domingo, P, Prieto, P, Mur, I, Pérez, JAH, Guimaraes, MP, Villarroya, J, Gutiérrez, MD, Mateo, MG, Domingo, JC, Planavila, A, Villarroya, F, Giralt, M, Cereijo, R. Reduced circulating levels of CXCL14 are associated with cardiovascular damage in people living with HIV. EUROPEAN JOURNAL OF PHARMACOLOGY. 2025; 1003DOI:10.1016/j.ejphar.2025.177996. PMID:40714072. IF:4.700(Q1/2D).

03/10/2023 Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.

Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz-Brito V, Peñafiel J, Tiraboschi J, Morenilla S, Garcia B, Soriano I, Podzamczer D, Imaz A. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.. JOURNAL OF INFECTIOUS DISEASES. 2023; 228(7)DOI:10.1093/infdis/jiad304. PMID:37526315. IF:(Q/D).

05/09/2023 Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2023; 78(9)DOI:10.1093/jac/dkad247. PMID:37539492. IF:3.900(Q1/3D).

01/10/2023 Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.

Lasaga M, Río P, Vilas-Zornoza A, Planell N, Navarro S, Alignani D, Fernández-Varas B, Mouzo D, Zubicaray J, Pujol RM, Nicoletti E, Schwartz JD, Sevilla J, Ainciburi M, Ullate-Agote A, Surrallés J, Perona R, Sastre L, Prosper F, Gomez-Cabrero D, Bueren JA. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282418. PMID:37021532. IF:10.100(Q1/2D).

12/02/2024 The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.

Viñolas N, Mezquita L, Corral J, Cobo M, Gil-Moncayo F, Paz-Ares L, Remon J, Rodríguez M, Ruano-Raviña A, Conde E, Majem M, Garrido P, Felip E, Isla D, de Castro J. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.. Clinical & Translational Oncology. 2024; 26(2)DOI:10.1007/s12094-023-03262-x. PMID:37490262. IF:2.500(Q3/6D).

01/12/2023 Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis.

Campos F, Téres R, Sebio A, Bettim BB, Martinez-Trufero J. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis.. CLINICAL ONCOLOGY. 2023; 35(12)DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3.200(Q2/5D).

01/10/2023 Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28)DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42.100(Q1/1D).

01/09/2023 Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial.

Casanovas-Álvarez A, Sebio-Garcia R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García-Valdecasas B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial.. PHYSICAL THERAPY. 2023; 103(9)DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3.500(Q1/1D).

01/09/2023 Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.

Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.. CLINICAL CANCER RESEARCH. 2023; 29(17)DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:10.400(Q1/1D).

27/08/2023 Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients.

Escuin D, López-Vilaró L, Bell O, Mora J, García-Valdecasas B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients.. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(17)DOI:10.3390/ijms241713293. PMID:37686099. IF:4.900(Q1/3D).

11/07/2025 YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features

Fumagalli, C, Orellana, R, Bagué, S, Ferré, M, Gonzalez, A, Catasus, L, Llauger, J, Peiró, A, Alarcón, PZ, Majercakova, K, Terés, R, Karanian-Philippe, M, Tirode, F, Antonescu, CR. YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features. GENES CHROMOSOMES & CANCER. 2025; 64(7)DOI:10.1002/gcc.70059. PMID:40879254. IF:2.800(Q2/5D).

01/03/2026 Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Paz-Ares, L, Veillon, R, Majem, M, Zhou, CC, Tang, KJ, Kim, SW, Richardson, G, Girard, N, Sanborn, RE, Mansfield, AS, Park, K, Schuchard, J, Diels, J, Sermon, J, Bhattacharya, A, Lorenzini, P, Wortman-Vayn, H, Knoblauch, RE, Agrawal, T, Baig, M, Ono, A, Sabari, JK. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. LUNG CANCER. 2026; 213DOI:10.1016/j.lungcan.2025.108788. PMID:41671629. IF:4.400(Q1/2D).

08/02/2026 Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis

Mateos, L, Jiménez-Fonseca, P, Gallego, J, Lecumberri, A, Custodio, A, de Castro, EM, San Gil, RH, Montes, AF, Limon, ML, Vidal-Tocino, R, Cano, JM, Robles, JL, Gil, M, Eyzaguirre, DA, Zafra, GM, Mérida-García, AJ, Fernández, AF, Fernández, PR, Hierro, C, Riesco, MC, Araque, MG, Martín, MR, Pimentel, P, Visa, L, Cerdá, P, Granja, M, Blanco, ABR, Gutiérrez, L, Carmona-Bayonas, A. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. BRITISH JOURNAL OF CANCER. 2026; 134(3)DOI:10.1038/s41416-025-03264-2. PMID:41298815. IF:6.800(Q1/2D).

01/02/2026 Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry

López-López, C, de Castro, EM, Montes, AF, Orozco, EJ, Peraita, SL, Vera, R, Cerdá, P, Calvo, M, Paredes, BG, de Mena, ML, La Casta, A, Gallego, J, Adeva, J, Cano, JMC, Ruiz-Casado, A, Vidal-Tocino, R, García-García, T, Pazo-Cid, R, Garrote, MR, Sastre, J. Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04010-z. PMID:40782167. IF:2.500(Q3/6D).

01/02/2026 Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

Molassiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, L, Stimamiglio, V, Alonzi, A, Tilola, SO, Bonizzoni, E, Vázquez, EB, Buchler, T, Cheng, Y, Christoph, DC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanová, M, Aapro, M. Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial. ANNALS OF ONCOLOGY. 2026; 37(2)DOI:10.1016/j.annonc.2025.10.017. PMID:41110696. IF:65.400(Q1/1D).

01/02/2026 Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

Gonzalez-Cao, M, Berciano-Guerrero, MA, Muñoz-Couselo, E, Manzano, JL, Cerezuela-Fuentes, P, Crespo, G, Soria, A, de Miguel, PA, Sanz, LG, de la Rosa, CA, Castaño, AG, Puértolas, T, Espinosa, E, Medina, J, Bellido, L, Berrocal, A, Majem, M, Castro, RL, Fernandez, LA, Garcia, F, de la Borbolla, MR, Algarra, SM, Márquez-Rodas, I. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Clinical & Translational Oncology. 2026; 28(2)DOI:10.1007/s12094-025-04018-5. PMID:40841506. IF:2.500(Q3/6D).

01/02/2026 Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

Rueda, A, Garcia-Leon, A, Arena, LA, Mendoza, JI, Avino, A, Fabrega, C, Eritja, R, Paez, D, Alba-Castellon, L, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I, Unzueta, U. Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates. Materials Today Bio. 2026; 36DOI:10.1016/j.mtbio.2025.102698. PMID:41560806. IF:10.200(Q1/1D).

17/01/2026 Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study

Borrego, MR, Lopez-Bravo, DP, Vila, MM, Pérez-García, JM, Fernández, M, Tormo, SB, García-Saenz, JA, Lema, L, Garau, I, Cortez, P, Torres, AA, Conejo, EA, Calvo, I, Ferrer, N, Blancas, I, Amillano, K, Santasusagna, S, Benderra, MA, Alcalá-Lopez, D, Antonarelli, G, Sampayo-Cordero, M, Llombart-Cussac, A, Cortés, J. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. EUROPEAN JOURNAL OF CANCER. 2026; 233DOI:10.1016/j.ejca.2025.116161. PMID:41371050. IF:7.100(Q1/2D).

17/01/2026 Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

Toledano-Fonseca, M, Cano-Osuna, MT, Elez, E, Soto-Alsar, J, Paáez, D, Fernández-Montes, A, Graña, B, Salud, A, Yubero, A, Macías, I, Quintero, G, López-López, C, Fernández-Rodríguez, T, García-Ortiz, MV, Sastre, J, García-Alfonso, P, Rodríguez-Ariza, A, Aranda, E. Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70103. PMID:40747746. IF:3.600(Q1/2D).

06/01/2026 Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study

Mirallas, O, Ruiz-Pace, F, Velilla, G, Gómez-Puerto, D, Gorria, T, Yaringaño, J, Martínez-Monino, A, López-Valbuena, D, Vaz, MA, Hernandez, A, Martínez-Saez, E, Sorolla, MA, Castro-Henriques, M, Bardaji, JL, Di Muzio, A, Gallego, O, Martínez-García, M, Domenech, M, Carles, J, Balaña, C, Pineda, E, Dienstmann, R, Vieito, M, Sepúlveda, JM. Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study. npj Precision Oncology. 2026; 10(1)DOI:10.1038/s41698-025-01247-3. PMID:41495434. IF:8.000(Q1/2D).

20/12/2025 A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer

O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).

05/12/2025 VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

Salazar, J, Arranz, MJ, Martin-Broto, J, Serra, M, Palmerini, E, Martínez-García, J, Juan-Ribelles, A, Andion, M, Martinez-Trufero, J, Gutiérrez, G, Echebarria-Barona, A, Vaz-Salgado, MA, Regueiro, A, Alvarez, R, Valverde, C, Luna, P, Blay, P, Sebio, A. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol. Pharmaceuticals. 2025; 18(12)DOI:10.3390/ph18121855. PMID:41471344. IF:4.800(Q1/2D).

01/12/2025 Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup

Tsuboi, M, Wakelee, H, Spicer, JD, Gao, S, Liberman, M, Kato, T, Chen, KN, Dooms, C, Majem, M, Martinengo, GL, Bylicki, O, Abreu, DR, Halmos, B, Jones, DR, Chaft, J, Reck, M, Jense, E, Keller, SM, Samkari, A, Garassino, MC. Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.10.607. PMID:. IF:65.400(Q1/1D).

30/11/2025 Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?

Molina-Pérez, MA, Martínez-Recio, S, Barba, A, Portu, M, Sanz-Beltran, J, Majem, M. Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?. Translational Lung Cancer Research. 2025; 14(11)DOI:10.21037/tlcr-2025-866. PMID:41367561. IF:3.500(Q1/3D).